This content is only available within our institutional offering.

22 Feb 2023
FY22 above expectation, multiple catalysts in 2023

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
FY22 above expectation, multiple catalysts in 2023
UCB (UCB:EBR), 0 | UCB S.A. (UCB:BRU), 0
- Published:
22 Feb 2023 -
Author:
Christophe Dombu Youta, PhD -
Pages:
5 -
FY 2022 figures are better than expected, showing a strong business resilience facing generic competition.Many product launches expected in 2023 should mark the end of the portfolio transition period and fuel the stock's momentum.Profitability in 2023 should still be impacted by multiple factors (inflation, tax rate, pre-launch expenses...), but we see a very positive outlook beyond.We will adjust our model following this publication and after the analyst conference this afternoon.